Quote | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
Last: | $1.84 |
---|---|
Change Percent: | 4.07% |
Open: | $1.7555 |
Close: | $1.84 |
High: | $1.85 |
Low: | $1.751 |
Volume: | 16,113 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H’24 BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- ...
Message Board Posts | VYNE Therapeutics Inc Com (NASDAQ:VYNE)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $VYNE 26% v1,5M c.226 f58,035M H.23 ML.11 lod.16 | znewcar1 | investorshangout | 01/06/2023 10:08:06 PM |
znewcar1: VYNE 31% v42,8M c1.20 f53,5M H1.3 S1.1 | znewcar1 | investorshangout | 12/06/2021 9:23:34 PM |
The follow-on order took awhile but it did fill. | jugs | investorshub | 11/24/2020 8:38:31 PM |
Picked up 300 $VYNE today at $1.64. Just | jugs | investorshub | 11/24/2020 7:49:26 PM |
We will fix that when it's time for | jugs | investorshub | 11/24/2020 4:58:44 PM |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H’24 BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- ...
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 BRIDGEWATER, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (...